Partners

Stragen is a privately-owned, international healthcare company based in Geneva (Switzerland). Founded in 1990, Stragen Healthcare Group initially focused on the development, registration and worldwide distribution of generic and generic+ drug products with franchise in hospital supplies and women's health and more recently on biopharmaceuticals. Leveraging on a strong pharmaceutical expertise, Stragen increased the scope of activities and developed several related business units: New Molecules, Consumer Health and Services. Stragen employs about 100 collaborators and exports in more than 60 countries through an extensive network of local partners and affiliates.
Lyonbiopole is the one-stop shop for healthcare innovation in Rhône-Alpes, France. It aims at supporting the emergence and development of innovative technologies, products and services for a more personalized medicine to the patient's benefit
Bpifrance finances businesses from the seed phase to transfer to stock exchange listing, through loans, guarantees and equity.
Bpifrance has three goals:
• to accompany businesses in their growth
• to prepare tomorrow’s competitivity
• to develop an ecosystem that favours entrepreneurship
The mission of the Cystic Fibrosis Foundation is to cure cystic fibrosis and to provide all people with the disease the opportunity to lead full, productive lives by funding research and drug development, promoting individualized treatment, and ensuring access to high-quality, specialized care.
Respiratory infections, frequently caused by drug-resistant bacteria, are the main cause of disease and death in people with cystic fibrosis (CF) and bronchiectasis (BE). Thanks to inhaled antibiotics, patients now live longer than ever before and enjoy a better quality of life. However, infections are increasingly becoming resistant to the few drugs available, putting patients’ lives at risk. The iABC project is advancing the development of two inhaled antibiotics for patients with CF and BE. It is also working to identify ways of improving clinical trials of treatments for these serious diseases.